Amir SohailNEW YORK, Aug. 10, 2026 (ZM NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a class action has been filed on behalf of shareholders who purchased securities between February 28, 2024 and February 25, 2026. Find out if you might be eligible to recover losses. You may also reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
PRCT shares declined more than 75%, or approximately $75.00 per share, from an all-time high of about $100.00 to less than $25.00 after serial disclosures. Those wishing to serve as lead plaintiff must act by September 22, 2026.
PROCEPT BioRobotics Timeline Disclosure Events
The securities action alleges that PROCEPT BioRobotics timeline disclosure events show an escalating pattern: strong handpiece utilization statements in 2024, continued assurances in early 2025, reduced handpiece expectations in late 2025, and first-time procedure data in February 2026.
The complaint recounts that Procept’s valuation depended heavily on recurring handpiece revenue and the perceived utilization of installed AquaBeam Robotic Systems. As detailed in the action, investors allegedly were not told that a discount program incentivized bulk handpiece orders beyond actual procedure demand.
Timeline of Alleged Disclosure Failures
- February 2024: Procept reported sharply higher U.S. handpiece revenue and attributed growth to increased utilization and commercial execution.
- May 2024: Management allegedly reassured investors that handpiece orders and procedures remained aligned and that customers ordered as needed.
- April 2025: CFO Kevin Waters maintained full-year expectations of approximately 52,500 handpieces and cited confidence in quarterly procedure volumes.
- August 2025: Procept announced deteriorating handpiece shipments, guidance below consensus by nearly 500 units, and significant commercial leadership changes.
- November 2025: Procept reduced annual handpiece guidance by 1,000 units for field inventory optimization.
- February 2026: Procept disclosed actual procedure data, a 30% sequential handpiece unit contraction, and more than 10,000 units of cumulative excess field inventory.
Why the Sequence Matters to PRCT Shareholders
The lawsuit chronicles an alleged gap between reported handpiece sales and actual procedure demand. Plaintiffs contend the delayed disclosure of procedure data allowed investors to continue evaluating Procept as if handpiece growth reflected durable recurring demand.
“Timely disclosure of material developments is fundamental to fair and efficient markets. Here, the alleged progression from utilization assurances to inventory optimization and first-time procedure disclosures raises important questions for PRCT shareholders.” — Joseph E. Levi, Esq.
Click here to submit your information and learn more about the case or call (212) 363-7500.
Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the PRCT Lawsuit
Q: Who may be eligible in the PRCT investor lawsuit? A: Investors who purchased PRCT stock or securities between February 28, 2024 and February 25, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether shares are still held.
Q: What specific misstatements does the PRCT lawsuit allege? A: The complaint alleges PROCEPT BioRobotics Corporation made materially false or misleading statements regarding handpiece utilization, the relationship between handpiece sales and actual procedures, field inventory levels, and the effects of an undisclosed discount program.
Q: What court was the PRCT class action filed in? A: The case was filed in the United States District Court for the Northern District of California, San Jose Division, and asserts claims under the federal securities laws.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the class. Lead plaintiffs are typically investors with significant documented losses and provide oversight of how the case proceeds.
Q: What documents should PRCT investors gather? A: Investors should preserve brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any sale dates and sale prices.
Q: What if I already sold my PRCT shares, can I still recover losses? A: Yes. Eligibility generally depends on when shares were purchased and whether losses were suffered
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
Publication Partner: ZM Newswire – Powered By Zeest Media
